Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early December after reporting positive data related to its oral obesity pill.

A study testing aleniglipron on obese or overweight patients, with one or more co-morbidities tied to weight, demonstrated a weight loss of 11.3% after being treated for 36 weeks at a dosage of 120 mg. This was a significant development, given that most of the market is concentrated in injectables.

Structure Therapeutics Inc. (NASDAQ:GPCR) also shared that there is another clinical research ongoing, testing participants with a 240 mg dose, which produced even better results, with a weight loss of 15.3% at 36 weeks.

In other news, on December 17, the company announced that it was beginning the first human-based trial of ACCG-2671, an oral small-molecule amylin receptor to treat obesity.

Wall Street analysts have a bullish outlook for the stock, with a consensus Strong Buy rating and a one-year average share price target of $104, representing an upside of 49.94%, as of the close on January 12.

Recent analyst updates include one from LifeSci Capital on January 6, where it reiterated a Buy rating on the stock with a price target of $107. This followed BMO Capital maintaining its Outperform rating on January 2, with a price target of $130.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a biotechnology company focused on the development of treatments for chronic metabolic conditions.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.